Andrew Zelenetz, MD, reviews the diagnosis and treatment plan for a 77-year-old man with relapsed chronic lymphocytic leukemia (CLL) while highlighting several treatment options.
EP. 1: A 77-Year-Old Man with Chronic Lymphocytic Leukemia
Andrew Zelenetz, MD, outlines the case of a 77-year-old man with chronic lymphocytic leukemia.
EP. 2: First-line Treatment Options in CLL
A key opinion leader highlights alternative treatment options to ibrutinib in the first-line setting for chronic lymphocytic leukemia.
EP. 3: Change in Therapy for CLL Due to Development of Atrial Fibrillation
Patient is switched for treatment of chronic lymphocytic leukemia from ibrutinib to idelalisib + rituximab due to development of atrial fibrillation.
EP. 4: Idelalisib + Rituximab in Previously Treated CLL Patients
Review of a phase III trial of idelalisib + rituximab in previously treated patients with chronic lymphocytic leukemia (CLL).
EP. 5: Management of Idelalisib Associated Diarrhea
Andrew Zelenetz, MD, offers tips for management of idelalisib-associated diarrhea during treatment for chronic lymphocytic leukemia.
EP. 6: What is the Role of PI3K Inhibitors in the Treatment of CLL?
Andrew Zelenetz, MD, offers guidance on how PI3Ki (phosphoinositide 3-kinase inhibitors) fit into the treatment landscape of chronic lymphocytic leukemia.
EP. 7: Current and Future Challenges in the Treatment of CLL
Andrew Zelenetz, MD, reflects on the impact of moving agents to the frontline for treatment of chronic lymphocytic leukemia and how that impacts treatment decisions in relapsed/refractory chronic lymphocytic leukemia.
2 Clarke Drive Cranbury, NJ 08512